Mumme, Hope L.
Raikar, Sunil S.
Bhasin, Swati S.
Thomas, Beena E.
Lawrence, Taylor
Weinzierl, Elizabeth P.
Pang, Yakun
DeRyckere, Deborah
Gawad, Chuck
Wechsler, Daniel S.
Porter, Christopher C.
Castellino, Sharon M.
Graham, Douglas K.
Bhasin, Manoj
Funding for this research was provided by:
Children’s Oncology Group - Alexis and Jerry Bednyak Award for High Risk Leukemia
CURE Childhood Cancer
Emory Startup Funds
Article History
Received: 4 May 2023
Accepted: 29 September 2023
First Online: 16 October 2023
Declarations
:
: All patient BM samples sequenced in our lab were obtained from the Aflac Cancer and Blood Disorders Center Biorepository within the Children’s Healthcare of Atlanta (CHOA) that was approved by the institutional review board at Emory University, Atlanta, GA (Protocol #00,034,535). Written informed consent was provided by parents or legal guardians for pediatric patients to permit the use of biological material in accordance with a protocol that was approved by the institutional review board.
: Not applicable.
: MB serves on the board of Canomiks Inc. as chief scientific advisor and has equity in it. DKG and DD hold equity in Meryx Inc. SSB serves as CEO of Anxomics LLC and has equity in it. The remaining authors declare no other competing interests.